COVID-19 Diagnosed by Serological Antibody Test: A Case Report

The new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in Wuhan, China, is causing a pandemic. With an increased understanding of the disease, the diagnosis and treatment guidelines are being updated and improved. In addition to nucleic acid detection, antibody detection kits are also being developed and approved. A medical worker suspected of having COVID-19 in our hospital had fatigue and loss of appetite and pulmonary infection indicated by CT, but the nucleic acid test was negative three times. Finally, she was confirmed to have COVID-19 by a serological antibody test. After rest and oral antiviral treatment, she recovered and returned to work. This is a case report that focuses on suspected mild patients who tested negative for nucleic acids. Such a group of patients had to choose home isolation treatment during the outbreak. The majority of them did not make a definitive diagnosis or rule out COVID-19 by the time they recovered. The antibody test is of great significance to identify infected patients with multiple negative nucleic acid tests. It can complement nucleic acid testing to enhance diagnostic efficiency. We have reviewed the literature and realized that further validation and standardization of serological tests are needed for more mature application of antibody tests to clinical diagnosis and vaccine development.

COVID-19, Serological antibody test, Case report

[1] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497-506.

[2] Live update: new coronavirus pneumonia outbreak map. 2020. accessable on: https://voice.baidu.com/act/newpneumonia/newpneumonia/?from=osari_pc_3. (accessed 2020/8/3)

[3] Coronavirus (COVID-19) events as they happen. 2020. accessable on: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen. (accessed 2020/3/13)

[4] The Central People’s Government of the People’s Republic of China. 2020. accessable on: http://www.gov.cn/ zhengce/zhengceku/2020-03/04/5486705/files/ae61004f930d47598711a0d4cbf874a9.pdf. (accessed 2020/3/13)

[5] Xiang F, Wang X, He X, et al. Antibody Detection and Dynamic Characteristics in Patients with COVID-19. CLIN INFECT DIS. 2020.

[6] Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Res-piratory Specimens of Infected Patients. N Engl J Med. 2020;382:1177-1179.

[7] Ning Y, Hou X, Lu W, et al. Application of the Technology of Serum Specific Antibody in Detection COVID-19. Medical Journal of Peking Union Medical College Hospital. 2020;1-9.

[8] Yongchen Z, Shen H, Wang X, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. EMERG MICROBES INFEC. 2020;9:833-836.

[9] Zhang W, Du R, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. EMERG MICROBES INFEC. 2020;9:386-389.

[10] Long Q, Liu B, Deng H, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. NAT MED. 2020;26:845-848.

[11] Meyer B, Drosten C, Muller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. VIRUS RES. 2014;194:175-183.

[12] Okba N, Muller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. EMERG INFECT DIS. 2020;26:1478-1488.

[13] Touma M. COVID-19: molecular diagnostics overview. Journal of molecular medicine (Berlin, Germany). 2020;98:947-954.

[14] Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BIOSCI TRENDS. 2020;14:69-71.

[15] Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. NEW ENGL J MED. 2020;382:929-936.